Completed PHASE2 INTERVENTIONAL NCT00123565

Hexadecasaccharide (SR123781A) in Patients With Unstable Angina or Non-ST-Segment Elevation Myocardial Infarction (SHINE)

A Randomized Dose Ranging Study of Hexadecasaccharide Including Active Control, in Patients With Unstable Angina or Non-ST-Segment Elevation Myocardial Infarction Scheduled to Undergo Percutaneous Coronary Intervention (SHINE)

Sponsor: Sanofi

Conditions Coronary Atherosclerosis

Interventions Hexadecasaccharide (SR123781A)

Updated 8 times since 2017 Last updated: Aug 20, 2008 Started: Dec 31, 2004 Primary completion: May 31, 2007 Completion: May 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Coronary Atherosclerosis, this trial is completed. The trial is conducted by Sanofi and has accumulated 8 data snapshots since 2004. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

8 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE2
Oct 2025 — Present [monthly]

Completed PHASE2
Sep 2025 — Oct 2025 [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Dec 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sanofi

Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Bridgewater, United States , Buenos Aires, Argentina , Diegem, Belgium , Gouda, Netherlands , India, India , Istanbul, Turkey (Türkiye) , Laval, Canada , Macquarie Park, Australia , Moscow, Russia and 8 more locations